Much remains unknown about the genetics and pathophysiology underlying the neurodegenerative disease amyotrophic lateral sclerosis (ALS). We analyzed exome sequences from a cohort of 87 sporadic ALS (SALS) patients and 324 healthy individuals. TP73, a homolog of the TP53 tumor suppressor gene, had five rare deleterious protein-coding variants; in a separate collection of >2,900 ALS patients we identified an additional 19 rare deleterious variants in TP73. An in vitro C2C12 myoblast growth assay confirmed that these variants impair or alter TP73 function. In vivo mutagenesis of zebrafish tp73 using CRISPR led to impaired motor neuron development and abnormal axonal morphology, concordant with ALS pathology.
Together, these results demonstrate that TP73 is a risk factor for ALS, and identifies a novel dysfunctional cellular process in the pathogenesis of ALS.
Introduction:
Amyotrophic lateral sclerosis (ALS) is a fatal degenerative disease of motor neurons in the brain and spinal cord (Taylor et al., 2016) . Much remains unknown about the genetics and pathophysiology underlying this disease. Genetic factors are critical determinants of ALS pathogenesis, as 68% of familial ALS (FALS) and 17% of sporadic ALS (SALS) cases have an identifiable genetic risk variant (Gibson et al., 2017; Renton et al., 2014) . However, up to 61% of SALS risk has been attributed to genetic factors (Al-Chalabi et al., 2010; Keller et al., 2014) , suggesting that unknown genetic loci contribute to the development of SALS. To address this, we employed next-generation sequencing of a cohort of 87 SALS patients, together with in vitro and in vivo experiments, to identify and characterize the role of the TP73 gene, a member of the p53 family of transcription factors, in ALS. This discovery reveals an unexpected and previously undescribed dysfunctional cellular process involved in ALS pathogenesis.
Results:
VAAST and PHEVOR identify TP73 as an ALS risk gene To identify novel ALS risk loci, we obtained whole exome sequences from a cohort of 87 SALS patients from the University of Utah and 324 healthy control individuals from the Simons Simplex Collection (Gibson et al., 2017; Iossifov et al., 2014) . VAAST (Hu et al., 2013) was used to identify genes with excess deleterious nonsynonymous single nucleotide variants (SNVs) in ALS patients compared to unaffected controls. We excluded SNVs with an Exome Aggregation Consortium (ExAC) (Lek et al., 2016) non-Finnish European (NFE) minor allele frequency (MAF) above 0.001. PHEVOR (Singleton et al., 2014) was then used to re-rank the VAAST candidate genes on the basis of biochemical, cellular, and pathological functions similar to known ALS risk genes. Two known ALS risk genes, MAPT (rank: 3) and SOD1 (rank: 5), were among the top ten genes ranked by combined VAAST and PHEVOR analysis (Fig. 1 ).
The only gene to rank among the top five genes in both VAAST and PHEVOR was TP73 (Fig. 1) , which encodes tumor protein 73 (p73). TP73's VAAST score approached genome-wide significance after Bonferroni multiple test correction, and PHEVOR revealed that TP73 shares significant functional characteristics with known ALS genes. Four different rare missense SNVs in TP73 were found among five SALS patients (Fig. 1c ). An additional rare-seven amino acid inframe deletion variant (chr1:3646605 CCATGAACAAGGTGCACGGGGG>C; TP73:p.PMNKVHGG413-420P), which was not assessed by VAAST, was found in an SALS patient upon searching for indels. Five of the six TP73 protein-coding variants were confirmed by Sanger sequencing; one variant was an exome genotyping error (Supplementary Figure 1) . p73 is part of the p53 family of tumor suppressor transcription factors, which modulate the expression of target genes to affect cell-cycle arrest, apoptosis, and cellular differentiation (Kaghad et al., 1997; Moll and Slade, 2004) . Trp73 -/-mice exhibit brain defects without a spontaneous tumor phenotype (Yang et al., 2000) , demonstrating that p73 is required for central nervous system development (Moll and Slade, 2004) . Aged mice carrying one Trp73 null allele (Trp73 +/-) show progressive motor weakness and a reduced number of neurons in the motor cortex (Wetzel et al., 2008) .
TP73 is affected by deleterious variation at a similar rate to known risk genes in ALS patients
We next tested whether rare and deleterious TP73 protein-coding variants could be found in two replication cohorts. A TP73 missense SNV (chr1:3647559 G>A; TP73:p.A472T) was identified and verified by Sanger sequencing (Supplementary Figure 1) in an independent cohort of 53 whole-exome or whole-genome sequenced University of Utah ALS patients (Fig. 2 ). An additional 18 rare variants that alter the TP73 coding sequence were found in the ALSdb cohort (ALSdb, http://alsdb.org) of more than 2,800 whole-exome sequenced ALS patients (Cirulli et al., 2015) . Combining all analyzed cohorts, 24 different rare TP73 coding sequence variant sites (22 SNVs and 2 in-frame indels) were found among approximately 2,900 ALS patients (Fig. 2) , which is similar to the relative contribution of many other ALS risk genes (Renton et al., 2014) .
All 22 SNVs were predicted to be deleterious to TP73 function by MetaSVM (Dong et al., 2015) and had an NFE MAF < 0.0005 (Fig. 2 ).
ALS patient specific TP73 protein-coding variants impair or alter the function of p73
Next, we tested whether the identified TP73 protein-coding variants impair the function of p73. TP73 gives rise to two different main protein isoforms-TA-p73 and ΔN-p73-which have opposing functions (Moll and Slade, 2004) . TA-p73, which possesses an N-terminal transactivation domain, induces expression of gene targets (Moll and Slade, 2004) . Conversely, N-terminally truncated p73 (ΔN-p73) has oncogenic and transformative qualities because it inhibits the function of p53 and TA-p73 (Moll and Slade, 2004) . Of note, ΔN-p73 is the primary p73 isoform found in the brain and promotes neuronal survival by providing resistance to apoptotic insults (Pozniak et al., 2000; Walsh et al., 2004) . ΔN-p73 function can be assayed by overexpression in serum-deprived C2C12 myoblasts as it inhibits cell cycle withdrawal, impairs myoblast differentiation into myotubes, and decreases myosin heavy chain (MHC) staining (Cam et al., 2006) . All four TP73 variants identified in University of Utah ALS patients that also resulted in coding changes in ΔN-p73α, the canonical isoform ΔN-p73, were selected for functional testing. We tested the ability of wild-type (WT) ΔN-p73α and each selected variant to inhibit myoblast differentiation and MHC staining. Expression of WT ΔN-p73 in C2C12 cells resulted in impaired differentiation, consistent with previous studies (Cam et al., 2006) (Fig. 3) .
Cells expressing two of the four tested TP73 variants did not show inhibited differentiation, suggesting these mutations render ΔN-p73α nonfunctional (Fig. 3) . Three of the four tested TP73 variants resulted in a significant increase in myotube width (Fig. 3) (Hoshijima et al., 2016) . tp73 CRISPR mutagenized embryos had a significant reduction in the number of GFP-labeled SMN compared to uninjected controls or tyr CRISPR injected controls ( Fig. 4g-j ). These results demonstrate the impact of deleterious tp73 mutations on SMN development, illustrating a pathogenic correlation with motor neuron disease.
Previous studies have shown that p73 is required to prevent neuronal apoptosis (Pozniak et al., 2002; Walsh et al., 2004) . To determine whether the reduction in motor neuron number in tp73 CRISPR mutagenized animals was due to apoptosis, we quantified TUNEL + /GFP + co-labeled SMNs in Tg(Hb9:Gal4; UAS:GFP) embryos. We found a ~2-fold increase in TUNEL + GFP + SMN in tp73 CRISPR mutagenized animals compared to uninjected controls ( Fig. 4d-f ). This suggests that increased apoptosis in tp73 CRISPR mutants contributes to motor neuron number reduction.
Loss of p73 results in reduction of spinal motor neuron axonal branching
Several ALS zebrafish models (Benedetti et al., 2016; Ciura et al., 2013; Kabashi et al., 2011; Kabashi et al., 2010) have reported a significant reduction in SMN axon length early in development. To address SMN axon outgrowth, we injected mnx:GFP alone or in combination with tp73 CRISPR to quantify SMN axon length. We found that tp73 CRISPR mutagenized embryos exhibited a significant reduction in primary and secondary axonal branching length ( Fig. 4k-n) .
Taken together, these data indicate disruption of tp73 leads to a reduction in SMN number and axon branch length in development.
Discussion:
Our results show that deleterious TP73 protein-coding variants occur in ALS patients at a similar frequency to other known risk genes, that TP73 ALS variants impair normal function of p73, and that loss of p73 impairs motor neuron survival and axonal development. Yang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., et al. (2000) . p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404, 99-103. Fig. 1 . VAAST/PHEVOR analyses identify multiple genes burdened by deleterious variation in ALS patients. 
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Methods:
Samples and sequencing
The exome sequencing results of 87 European sporadic ALS (SALS) patients and 324
SSC control individuals from a previous study were used for this analysis (Gibson et al., 2017; Iossifov et al., 2014) . The detailed sequencing methods and quality-control measures can be found in that report. Experiments were approved by the University of Utah Institutional Review board. SALS patients seen at the University of Utah School of Medicine provided consent and were included in genetic studies. All patients were determined to have probable or definite ALS according to El Escorial revised criteria (Brooks et al., 2000) . Exome sequencing libraries were generated from patient DNA using the Gentra Puregene Blood Kit (Qiagen) and SeqCap EZ Exome Enrichment Kit (v3.0; Roche NimbleGen). In total, DNA from 96 SALS patients was gathered for genetic analysis. The patient characteristics, ancestry composition, and known genetic risk factors-including disease-associated ATXN2 and C9orf72 repeat expansions-of this ALS cohort have been previously described (Gibson et al., 2017) . Genomic reads were also obtained from 714 healthy individuals from the Simons Simplex Collection (SSC) to serve as controls (Iossifov et al., 2014) .
Exome sequencing libraries were sequenced on the Illumina HiSeq platform to generate 101-bp, paired-end reads. BWA-MEM (v0.7.12) was used to perform read alignment to the GRCh37 reference genome (Li, 2013) . Genomic read coordinate-based sorted and duplicate read marking was performed by Picard Tools (v1.130). A standard GATK best-practices pipeline was then used to generate joint variant calls for each analyzed individual as previously described (Gibson et al., 2017) .
VAAST and PHEVOR analysis
The variant calls from 87 European SALS patients and 324 SSC control individuals were then selected for VAAST/PHEVOR analysis. ADMIXTURE (Alexander et al., 2009 ) and smartpca (Patterson et al., 2006; Price et al., 2006) were previously used (Gibson et al., 2017) to determine that these individuals were of European descent and were specifically selected to control for population stratification effects. Genomic regions covered by less than five sequencing reads on average in the SALS and SSC cohorts were omitted from further analysis to control for coverage differences between the two cohorts. Variants with an ExAC (Lek et al., 2016) European MAF greater than 0.001 were removed from further consideration to reduce false-positive gene associations. This value corresponds approximately to the frequency of the most common allele known to cause ALS (Andersen et al., 1995) .
Genotype calls passing these criteria were analyzed by VAAST (Hu et al., 2013) to prioritize genes more burdened by deleterious variants in cases versus controls. Insertion and deletion (indel) variants were not used in the VAAST analysis as indel frequency-based filtering is difficult due to inconsistency in how they are reported in different datasets (Tan et al., 2015) .
VAAST was run assuming a dominant model of disease inheritance. Multiple test correction is required when using VAAST because it tests for an excess of burden in all genes in the genome.
Bonferroni correction was used to account for multiple hypothesis testing. As a result, a p-value of 2.57 × 10 -6 was required for a gene to be considered significantly burdened (α = 0.05; 19,492 genes tested). The output from VAAST is a ranked list of genes by burden significance. This output is then analyzed by PHEVOR (Singleton et al., 2014) in order to identify burdened genes that share similar functional characteristics to genes known to be associated with a phenotype of interest. PHEVOR first collects genes previously shown to be associated with a phenotype as provided by the Human Phenotype Ontology (HPO). PHEVOR then traverses multiple gene ontologies-such as the Gene Ontology, Mammalian Phenotype Ontology, and the Disease Ontology-using genes from the HPO gene list to find ontology nodes, and the genes contained within them, likely to be associated with the phenotype. PHEVOR then combines the degree of association a gene has with a particular phenotype with the gene burden calculations of VAAST to determine the PHEVOR score. The PHEVOR score is defined as the log10 ratio of how likely a gene is to be associated with a disease phenotype of interest versus a healthy phenotype.
The following Human Phenotype Ontology (HPO) (Kohler et al., 2017) terms were used by the PHEVOR analysis: amyotrophic lateral sclerosis (HP:0007354), abnormal motor neuron morphology (HP:0002450), motor neuron atrophy (HP:0007373), and frontotemporal dementia (HP:0002145).
Screening of ALS patients for deleterious TP73 variants and Sanger sequencing
The discovery SALS cohort was screened for indels in TP73 after performing VAAST as these variants were not assessed in this analysis, which found chr1:3646605
We utilized two replication cohorts to determine whether rare and deleterious TP73
protein-coding variants could be found outside of the discovery cohort. The first was a cohort from the University of Utah that contained exome and whole genome sequenced SALS patients.
More specifically, it contained nine exome sequenced non-European SALS patients who underwent genotype calling with the discovery cohort. It also included 44 SALS patients whose whole genomes were sequenced. These individuals came from a University of Utah ALS sequencing project that contained 70 ALS patients and eight unaffected relatives. Of these 70 ALS patients, 26 were also exome sequenced either in the discovery or University of Utah replication cohort and were not considered in this analysis. The collected DNA samples were 
TP73:p.A472T).
Sanger sequencing was used to validate the seven identified TP73 coding variants in the University of Utah ALS patients. Sanger sequencing confirmed the presence of all but one of the TP73 coding sequence variants. More specifically, the presence of a rare TP73 SNV (chr1:3649488 G>A; TP73:p.V586M) was confirmed in only one of the two ALS patients it was first identified in (Supplementary Figure 1) . The primers used for Sanger verification of these variants can be found in Supplementary Table 1. Cloning of wildtype and mutant ΔN-p73:
A DNA insert containing the ΔN-p73α coding DNA sequence (CDS) was then generated from a HA-p73α-pcDNA plasmid (a gift from William Kaelin; Addgene plasmid # 22102 (Jost et al., 1997)) by PCR (Supplementary Table 1 ). The coding sequence of ΔN-p73 was cloned into a pBABE-puro vector (a gift from Hartmut Land & Jay Morgenstern & Bob Weinberg, Addgene plasmid # 1764 (Morgenstern and Land, 1990)) using BamHI and SalI (New England Biolabs).
Patient variants were introduced into pBABE-ΔN-p73-puro using site directed mutagenesis (New England Biolabs) (Supplementary Table 1 C2C12 myoblasts were cultured in high glucose DMEM plus 20% HI FBS and 1% P/S.
For lentiviral infections, 50,000 C2C12s were seeded per well. Twenty µl of lentiviral supernatant was added to cells in growth medium containing 5 µg/ml polybrene. After 24 hours, medium was replaced with growth medium lacking polybrene. Forty-eight hours post infection, cells were incubated in growth medium plus 10 µg/mL blasticidin to select for successfully infected cells. Cells were continuously kept under blasticidin selection in all subsequent experiments. Twenty-four well plates were prepared for C2C12 differentiation experiments by adding 0.1% gelatin in dH20 to each well and incubating for fifteen minutes at 37C. Wells were rinsed with PBS and wells were seeded with 50,000 C2C12 cells in technical duplicate for each distinct genotype. Cells exposed to doxycycline (dox) were cultured in separate culture dishes from controls. Cells were exposed to either growth medium containing 1 µg/ml of doxycycline or normal growth medium. After 24 hours, cells were incubated in differentiation medium (DM) (10 µg/ml recombinant human insulin (Gibco), 2% HI horse serum (Thermo Fisher), and 1% P/S) with or without 1 µg/ml doxycycline. Cells were incubated in DM with or without doxycycline for four days before fixation with 70% ethanol. DM was changed every 48 hours.
After fixation and endogenous peroxidase inactivation, cells were blocked for one hour with blocking solution (5% donkey serum in PBS,0.3% TX-100, 0.2% Na Azide). Cells were incubated with anti-myosin heavy chain antibody (MF-20, DSHB) at a 1:100 dilution at 4C
overnight. Cells were washed with PBST and incubated with donkey-anti mouse conjugated to biotin secondary for 45 minutes at room temperature (Jackson ImmunoResearch). Cells were washed and Vector ABC reagent (Vector Laboratories, VECTASTAIN Elite ABC-HRP Kit #PK-6100) was added to cells and incubated for thirty minutes at room temperature. Cells were washed and Vector DAB substrate was added (Vector Laboratories, DAB Peroxidase (HRP)
Substrate Kit #SK-4100). Substrate was allowed to develop for 5 minutes at room temperature.
Cells were imaged using an EVOS Plate Reader (imaging was performed at the Fluorescence Microscopy Core Facility, a part of the Health Sciences Cores at the University of Utah). Control plates with no dox exposure were analyzed in biological duplicate and plates with dox exposure were analyzed in biological triplicate. Four images were taken of each technical replicate well for each genotype on both positive and negative doxycycline plates (though some images could not be used to measure either intensity or myotube width due to technical inadequacy). Three distinct measurements of myotube width were performed per image. Myotube width was measured using pixel length in Fiji (Schindelin et al., 2012) . Intensity staining was also calculated using Fiji. Myotube width and intensity values were normalized to the mean value of myotube width and mean intensity of pCLX-pTF-eGFP cells incubated in dox, respectively.
Unpaired two sample Mann-Whitney tests were used to compare normalized values using R. Pvalues were adjusted for multiple comparisons using the Bonferroni method in R.
Confirmation of doxycycline induced ΔN-p73 protein expression in C2C12 cells:
C2C12 cells of wildtype and each mutant genotype were incubated in growth medium plus or minus dox for 48 hours. Cells were then lysed with RIPA buffer (Abcam ab156034) containing Pierce protease inhibitor tablets (ThermoFisher). One hundred micrograms of protein were loaded per well in 4-12% Bis-Tris gels (ThermoFisher) and separated by SDS-PAGE using MOPS buffer (Thermo Fisher). Proteins were transferred to 0.45 um PVDF membranes (ThermoFisher) using a mini blot module (ThermoFisher) and blocked in 5% milk in PBST for one hour. Blots were incubated in primary antibody and 5% milk in PBST overnight at 4C. The primary antibodies used were anti-β-actin (ThermoFisher #MA5-15739) used at a 1:10,000 dilution and anti-ΔN-p73 (ThermoFisher #MA5-16183) used at 1.5 µg/mL. Cells were washed and incubated in secondary antibody for one hour at room temperature. The secondary antibody used was goat anti-mouse-HRP (Thermo Fisher # 31430) used at a 1:20,000 for anti-β-actin blots and 1:5000 dilution for anti-ΔN-p73 blots. Blots were developed using SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher#34578) for five minutes before visualization using x-ray film (GeneMate). Western blot images were processed using Fiji.
Zebrafish modeling of TP73 loss of function
Ethics Statement
All zebrafish experiments were performed in accordance of guidelines from the 
Immunofluorescence
Immunofluorescence was performed as previously described (Bonkowsky et al., 2008; Stevenson et al., 2012; Xing et al., 2012) . Antibodies used were: chicken anti-GFP (1:1000 dilution, Aves, GFP-1020), and goat anti-chicken Alexa 488 (1:400 dilution, Invitrogen, A11039). Additionally, nuclei were stained with 4,6-Diamidino-2-Phenylindole (DAPI, diluted 1:1000). Prior to staining, embryos were fixed, dehydrated, and stored as described above. For immunofluorescence, 72 hpf embryos were rehydrated from 100% MeOH to 1x PBST stepwise (MeOH: 100%, 75%, 50%, 25%, 1x PBST), and permeabilized with Proteinase K (1:1000,10 µg/ml) for 1 hour, washed in blocking solution (1x PBST, 1% dimethyl sulfoxide (DMSO), 2%
bovine serum albumin (BSA), 5% Normal goat serum (NGS)) for 2 hours, and incubated with primary antibodies diluted in staining solution (1x PBST, 1% DMSO, 2% NGS) overnight at 4°C. The following day embryos were washed several times in 1x PBST. Secondary antibody plus DAPI were diluted in staining solution, and incubated overnight at 4°C. After overnight incubation, embryos were washed several times in 1x PBST and cleared in 25% glycerol in 1x PBS solution for 30 minutes, followed by 50% glycerol overnight at 4°C. The following day embryos were washed in 80% glycerol for 30 minutes and mounted for imaging. For spinal motor neuron (SMN) number quantification, embryos were mounted with their dorsal surface facing toward the coverslip. For axonal outgrowth quantification, the lateral surface of the embryos faced toward the coverslip.
TUNEL staining
Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) was performed on whole-mount larvae (ApopTag Rhodamine In situ Apoptosis Detection Kit; Millipore). Embryos were fixed, dehydrated, and permeabilized as described for immunofluorescence. Briefly, embryos were incubated in equilibration buffer (Millipore) for 1 hour, followed by overnight incubation in TdT enzyme (Millipore) at 37°C. The following day, end-labeling was terminated with incubations in stop/wash buffer (Millipore), followed by several washes in 1x PBST. Next, embryos were incubated in working strength sheep antidigoxigenin rhodamine (Millipore) for 1 hour at room temperature. Labeling was stopped by several washes in 1x PBST and embryos were cleared and mounted for imaging as described above.
In situ hybridization
Anti-sense digoxigenin-labeled RNA probe was prepared for tp73 (ENSDARG00000017953). To generate probe, cDNA from 3 dpf larvae was amplified with the reverse primer containing a T7 RNA polymerase priming site (5'-CCAAGCTTCTAATACGACTCACTATAGGGAGA-3'). The tp73 gene specific primers used were: forward: 5'-AGCTCAGAGACCACCTCCAA-3', reverse: 5'-TTCCTCCAACACAACTGCTG-3'. Following PCR amplification, the product was checked for the correct band size by gel electrophoreses, and Sanger sequenced. RNA digoxigenin-labeled probe was synthesized by in vitro transcription using Dig RNA labeling kit (Sigma-Aldrich).
For in situ hybridization, 72 hpf embryos were fixed, dehydrated, and permeabilized as described above. After permeabilization, embryos washed briefly in Hybridization minus (Hyb-) solution (50% deionized formamide (Amresco), 0.1X saline-sodium citrate (SSC), 0.1% Tween 20 (Amresco)) for 5 minutes at 65°C, followed by a 1 hour prehybridization in Hybridization plus (Hyb+) solution (Hyb+ solution contains Hyb-solution plus: 5 mg/ml torula RNA (SigmaAldrich), 50 µg/ml heparin (Sigma-Aldrich)) at 65°C. Embryos where then incubated overnight at 65°C with Dig labeled RNA probe diluted in Hyb+ buffer. The following day, embryos were washed at 65°C in 50% formamide in 2XSSCT twice for 30 minutes each, followed by one 2XSSCT wash for 15 minutes, and finally two 0.2XSSCT washes for 30 minutes each. Next embryos were washed in blocking solution (100mM maleic acid, 150 mM NaCl pH 7.5, 2%
blocking reagent (Roche)) for 1 hour at room temperature, followed by incubation with antidigoxigenin alkaline phosphatase (AP) (Roche, 1:5000) overnight at 4°C. The following day, embryos were developed with the addition of BM purple AP substrate (Sigma-Aldrich). In situ development was stopped with several washes in 1x PBST and cleared as previously described.
In situ hybridization combined with immunohistochemistry
In situ hybridization was performed as described above. Embryos were then cryoprotected by washing briefly in 5% sucrose (in 1x PBS) followed by overnight incubation in 30% sucrose at 4°C. Samples were then embedded in optimal cutting temperature compound (OCT, 4583) , and stored at -80°C until use. Sections were cut at 20 µm thickness.
sequencing the tp73 CRISPR targeted region was TA-cloned into a pCR4-TOPO TA (Invitrogen) vector. Four clones per embryo were Sanger sequenced.
Transient transgenic zebrafish generation
One-cell stage wild-type embryos were either injected with mnx:GFP (18 ng/µl) alone, or in combination (mnx:GFP, 50 ng/µl) with tp73 sgRNA (420 ng/µl). All CRISPR injected embryos were also injected with 800 ng/µl Cas9 protein (IDT). At 72 hpf, embryos were fixed and dehydrated as described above for immunofluorescence and in situ staining.
Spinal motor neuron (SMN) quantification
To assess the number of SMN, 72 hpf Tg(Hb9:Gal4; UAS:GFP) transgenic embryos were stained for GFP, DAPI, and mounted as described. Slides were imaged on a Nikon A1 
Spinal Motor Neuron Axonal characterization
To assess axonal outgrowth, transient transgenic 72 hpf immunostained embryos were mounted as described. A set of 21 slices of 5µm step size (50µm above and 50µm below of the area containing the highest number of SMN) was taken in a Nikon A1 microscope using identical settings (10X objective, 2.5X zoom, 1024 size, 6.2 ms / pixel). Confocal stacks of maximal 
